Breaking News

Citigroup Profit Falls 96% on Costs to End Mortgage-Bond Probe
Tweet TWEET

LifeMap Sciences, a Subsidiary of BioTime, Signs Definitive Distribution Agreement with ProSpec-Tany TechnoGene

  LifeMap Sciences, a Subsidiary of BioTime, Signs Definitive Distribution
  Agreement with ProSpec-Tany TechnoGene

Business Wire

ALAMEDA, Calif. -- November 20, 2012

LifeMap Sciences, Inc. a subsidiary of BioTime, Inc. (NYSE MKT: BTX) announced
today that it has signed a definitive distribution agreement with ProSpec-Tany
TechnoGene Ltd. (ProSpec). In the beginning of 2013, LifeMap Sciences will be
offering more than a 1000 recombinant proteins and antibodies, many of which
are related to stem cell research, such as growth factors, signaling
molecules, differentiation factors, hormones, cytokines and chemokines.
LifeMap Sciences is the principal marketing and sales arm for BioTime’s
cell-based products and related reagents for research use in academia,
research hospitals, and biotech and pharma companies. ProSpec’s innovative
products will complement the current BioTime research product lines available
via the recently launched LifeMap BioReagents™ portal, including PureStem™
human progenitor cell lines, PureStem™ packages, clinical and research grade
human embryonic stem cell lines (hES), HyStem^® hydrogels, culture media, and
cell differentiation kits.

LifeMap BioReagents™ offering of BioTime products and the upcoming addition of
the ProSpec products reflects the company’s initial execution of a strategy to
market a growing catalog of research products to aid scientists in a variety
of fields, including stem cell research, developmental biology, mechanisms of
various human diseases, drug discovery, and therapeutic discovery and
development. LifeMap Sciences holds the exclusive, worldwide license to market
GeneCards^®  (www.genecards.org), with over 12 million page visits per year
from hundreds of thousands of unique users worldwide, and MalaCards
(www.malacards.org), and plans to launch LifeMap Discovery™, its database for
biomedical and stem cell research, later this quarter. LifeMap BioReagents™
will be integrated with the GeneCards^®, MalaCards, and LifeMap Discovery™
databases,  thereby providing hundreds of thousands of biomedical researchers
accessing these databases a means of identifying reagents that can enhance
their research and discovery efforts.

These databases currently feature targeted links to the various BioTime
PureStem™ human progenitor cell lines, PureStem™ packages, and clinical and
research grade human embryonic stem cell lines, and will soon add links to the
ProSpec manufactured products. These links enable researchers who access the
databases to become familiar with, and purchase, products that relate directly
to the types of genes, cells, or diseases that they are studying and can
assist them in various research projects.

“We are pleased to establish this distribution relationship with ProSpec,”
stated Yaron Guan-Golan, Head of Marketing at LifeMap Sciences. “This
agreement represents a significant step for our LifeMap BioReagents portal,
enabling us to place high quality recombinant proteins in the hands of our
research community user base, and increasing our product portfolio and brand
awareness.”

About LifeMap Sciences, Inc.

LifeMap Sciences’ (www.lifemapsc.com) core technology and business is based on
its integrated database suite, the discovery platform for biomedical and stem
cell research. This platform includes GeneCards^®, the leading human gene
database; LifeMap Discovery™, the database of embryonic development, stem cell
research, and regenerative medicine; and MalaCards, the human disease
database. LifeMap Sciences also markets PanDaTox, an innovative, recently
developed, searchable database that can aid in the discovery of new
antibiotics and biotechnologically beneficial products.

In addition to database offerings, LifeMap Sciences is BioTime’s principal
marketing subsidiary for research products, including PureStem™ human
progenitor cell lines, GMP human embryonic stem (hES) cell lines, ESpan™
growth media for progenitor cell lines, and cell differentiation media for
non-therapeutic uses, via its LifeMap BioReagents™ portal. LifeMap Sciences
will utilize its databases as part of its online marketing strategy to reach
life sciences researchers at biotech and pharmaceutical companies and at
academic institutions and research hospitals worldwide.

In a therapeutic discovery collaboration with BioTime, LifeMap’s scientists
utilize LifeMap’s proprietary platform, including LifeMap Discovery™, its stem
cell database along with the GeneCards^® and MalaCards integrated database
suite, to aid in the development of BioTime’s proprietary PureStem™ human
progenitor cell lines into products for the treatment of human diseases,
especially degenerative diseases that might be treatable with cell replacement
therapies. The LifeMap Discovery™ platform will be used to select the
progenitor cell lines that are most likely to facilitate the development of
cell-based regenerative medicine therapies for a wide range of diseases.

About ProSpec-Tany TechnoGene Ltd.

ProSpec (Protein-Specialists) is a leading biotechnology company having over
19 years of experience specializing in production of bacterial-derived
recombinant proteins. ProSpec produces a wide array of Cytokines, Growth
Factors, Chemokines, Hormones, Enzymes, Viral Antigens and many other
recombinant proteins.

ProSpec’s proprietary protein purification technologies with over a decade of
extensive experience result in low production costs, high yield, production
efficiency, utmost pure products and uncompromising biological activity at
competitive prices. ProSpec provides custom in-house production services of
recombinant proteins tailored to the customer's needs.

ProSpec provides proteins, services and technologylicense to a broad range of
customers around the globefrom academic and government research
institutions,biotechnology and pharmaceutical companies, as well as hospitals
and reference laboratories.

ProSpec's goal is to supply proteins which are crucial to the research
industry to meet and exceed quality, consistency and requirements by our
customers worldwide. The company welcomes partnerships with pharmaceutical and
industrial companies for development of future proteins.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company
focused on regenerative medicine and blood plasma volume expanders. Its broad
platform of stem cell technologies is enhanced through subsidiaries focused on
specific fields of application. BioTime develops and markets research products
in the fields of stem cells and regenerative medicine, including a wide array
of proprietary PureStem™ cell lines, HyStem^® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (formerly known as
HyStem^®-Rx), a biocompatible, implantable hyaluronan and collagen-based
matrix for cell delivery in human clinical applications. BioTime's therapeutic
product development strategy is pursued through subsidiaries that focus on
specific organ systems and related diseases for which there is a high unmet
medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd.
is developing therapeutic products derived from stem cells for the treatment
of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte
Corporation is developing therapeutic applications of stem cells to treat
orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation,
focuses on the diagnostic and therapeutic applications of stem cell technology
in cancer, including the diagnostic product PanC-Dx™ currently being developed
for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is
developing applications of BioTime's proprietary induced pluripotent stem cell
technology to reverse the developmental aging of human cells to treat
cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences,
Inc. markets GeneCards^®, the leading human gene database, and is developing
an integrated database suite to complement GeneCards^® that will also include
the LifeMap™ database of embryonic development, stem cell research and
regenerative medicine, and MalaCards, the human disease database. LifeMap will
also market BioTime research products. BioTime's lead product, Hextend^®, is a
blood plasma volume expander manufactured and distributed in the U.S. by
Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive
licensing agreements. Additional information about BioTime can be found on the
web at www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future
growth in research, technology, clinical development, and potential
opportunities for BioTime and its subsidiaries, along with other statements
about the future expectations, beliefs, goals, plans, or prospects expressed
by management constitute forward-looking statements. Any statements that are
not historical fact (including, but not limited to statements that contain
words such as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or commercialization of
potential products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking statements
and as such should be evaluated together with the many uncertainties that
affect the business of BioTime and its subsidiaries, particularly those
mentioned in the cautionary statements found in BioTime's Securities and
Exchange Commission filings. BioTime disclaims any intent or obligation to
update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list:
http://phx.corporate-ir.net/phoenix.zhtml?c=83805&p=irol-alerts

Contact:

BioTime, Inc.
Peter Garcia, 510-521-3390, ext 367
Chief Financial Officer
pgarcia@biotimemail.com
or
Judith Segall, 510-521-3390, ext 301
jsegall@biotimemail.com
or
LifeMap Sciences, Inc.
Kenneth Elsner, 781-826-7719
COO
ke@lifemapsc.com